Orkla ASA (ORK) Earnings Call Transcript & Summary

August 20, 2026

Oslo Bors NO Consumer Staples Food Products earnings 22 min

Earnings Call Speaker Segments

Annie Bersagel

executive
#1

Good morning, everyone, and welcome as we present Orkla's results for the second quarter. I'm Annie Bersagel, serving as Head of Investor Relations and Communications. Because of travel that had already been scheduled, our President and CEO, Nils Selte, isn't able to be with us today. Both the presentation and the Q&A will be handled by our CFO, Arve Regland. Before I hand things over to Arve, one reminder: we'll start with the video Q&A featuring our analysts, and afterward we'll move to questions coming in from the web. Should you have a question, feel free to send it in whenever you like, and we'll get to those at the very end. With that said, Arve, the floor is yours.

Arve Regland

executive
#2

Thank you, Annie, and good morning to all of you. The consolidated portfolio companies at Orkla posted organic top-line development that was flat for the quarter, along with EBIT growth of 2.5%. Taken as a whole, these results leave us dissatisfied. That said, Jotun turned in yet another strong quarter, which helped lift adjusted earnings per share by 3%. We kept executing against our capital allocation priorities, and in July we finished the 4 billion share buyback program that had been announced last November. Both during and after the quarter, portfolio companies announced a number of acquisitions in prioritized categories. The biggest among them was the acquisition of the European Candy Group by Orkla Snacks. Orkla Foods also announced that it would acquire a 40% stake in Go-Tan Group, which strengthens its position in sauces. That transaction closed on Tuesday this week. Both transactions reinforce existing category positions and support long-term growth. For the consolidated portfolio, volume/mix was down 1.3%. Broadly speaking, price increases were offset by lower volumes across several portfolio companies. The reversal of supported Easter phasing effects from the first quarter contributed negatively, alongside weaker volume development in parts of the portfolio. Underlying adjusted EBIT for the consolidated portfolio, inclusive of Orkla ASA, grew 2.5%. As this slide shows, development varied across the portfolio companies, and I will return to this in more detail.

Arve Regland

executive
#3

The EBIT margin came in at 10.5%, and development varied across the portfolio companies. During the previous quarter, we stated our expectation of higher costs for energy, transportation, and packaging stemming from the conflict in the Middle East. That expectation still stands. Although the danger of more serious near-term disruption looks smaller now than it did three months ago, uncertainty is still elevated. The longer-term indirect consequences for supply chains and input costs are less evident, and both when they will hit and how big they will be stay hard to pin down. Moving to Orkla's consolidated financial targets, underlying EBIT growth stood at 2.7% year-to-date, with growth slower during the first half of this year, yet taken together over the strategy period it remains inside the target range. The EBIT margin did not change from the first quarter, staying inside our target range of 10.5 to 11%, while return on capital employed fell somewhat relative to the first quarter, mirroring slower EBIT growth. Of the three targets, this one poses the greatest challenge, and work remains to be done. I'll now give a few more details on the financials. Reported revenues fell by 5%, and once currency translation effects are adjusted for, underlying revenues were flat. Reported EBIT adjusted likewise dropped by 5%, with the gap versus underlying figures again mainly attributable to currency consolidation effects.

Arve Regland

executive
#4

Other income for the quarter came to 97 million. The biggest factor there was the closing of the Nói Síríus divestment in Iceland, which happened during the quarter. Adjusted earnings per share rose 3% to NOK 1.60, and a 17% profit increase from Jotun, along with lower tax and financing costs, more than offset the drop in adjusted EBIT. Cash flow is quite steady versus last year, with cash flow from operations for the first half at 2.1 billion, and cash flow before capital allocation at 1.6 billion, roughly 200 million lower year-over-year. Turning to the capital allocation and leverage bridge, so far this year we have paid 6 billion in dividends — 6 million, 6 billion — and bought back shares for 2.3 billion. Expansion investments grew by about 300 million in the quarter, lifting the year-to-date figure to roughly 400 million. Acquisitions of companies comprise three bolt-on deals in Orkla Food Ingredients, and the sale of companies mainly reflects Orkla Snacks' divestment of its Icelandic business, which closed at the end of the second quarter. Net interest-bearing debt stood at 20.7 billion at quarter-end, equal to a net debt to EBITDA ratio of 2.2 times.

Arve Regland

executive
#5

A bit more color on the portfolio companies — and as I said, Jotun delivered another solid quarter. Revenue rose 11% on an underlying basis, mainly from higher volumes, and every segment and region added to sales growth, with Protective Coatings turning in the strongest performance. Negative currency translation effects kept dragging on the reported numbers, and Jotun has handled the Middle East conflict well, rolling out mitigating actions sooner than we had expected. Reported operating profit was up 13%, and underlying profit rose 21%. Even with difficult conditions, business units in the war-affected markets posted flat underlying sales development and a 2% gain in underlying operating profit. Raw material prices climbed significantly in the quarter, though by less than we had anticipated in the first quarter outlook. Gross margins improved, since higher premium sales, pricing measures, and ongoing cost control more than offset the rise in raw material costs. Note that margins still do not fully reflect the raw material price increase. Orkla's share of profit from Jotun rose 17% to 494 million. Jotun's outlook is still uncertain because of the conflict in the Middle East. The company anticipates some margin pressure over the coming quarters as the effect of higher raw material costs comes through.

Arve Regland

executive
#6

Should that conflict continue, its impact on business conditions, supply chains, and raw material markets will probably reach past the region. At Orkla Foods, organic revenues fell 1.3% during the quarter, while volume/mix came in at minus 2.3%. That partly reflects the reversal of the Easter timing benefits seen in Norway and Sweden during the first quarter. Volume/mix growth reached 1.4% in categories classified as growth priorities. Sweden continues to develop well, with positive market share trends. Development remains more challenging in Norway and Finland. Underlying EBIT rose 4%. EBIT growth was supported by improved product and category mix, lower marketing spend, and temporary lower fixed costs. Organic revenue declined 1.1% at Orkla Snacks. Volume growth of 0.5% was driven primarily by confectionery. Biscuits also contributed positively, while snacks volumes declined. Volume growth was also dampened by the Easter phasing effects. Lower prices were mainly related to chocolate products. Underlying EBIT increased 10%. The improvement was primarily driven by the chocolate recovery. In July, the company announced the acquisition of the European Candy Group to support further expansion of Bubs, and Orkla Snacks continues to invest in growth capacity. The new Smash production line at Nidar is operational.

Arve Regland

executive
#7

The third Bubs line in Jönköping is now up and running. Thanks to the partnership with Mount Franklin Foods, Bubs products can now be found in roughly 60,000 stores throughout the United States. At Orkla Home and Personal Care, organic revenues fell 2.5%, which reflected promotional phasing as well as some unfavorable Easter timing effects. Market shares keep rising in Norway and held steady in Sweden and Finland. Underlying EBIT grew 8.2%, lifted by systematic cost-out initiatives spanning the value chain. At Orkla Food Ingredients, organic revenue dropped 1.5%, with volume/mix down 2.1%. Sweet Ingredients posted positive volume/mix growth, whereas plant-based was hit by an unfavorable product mix. In Bakery, demand was soft across Central and Eastern Europe. Easter timing likewise weighed on volumes during the quarter. The drop in underlying EBIT was broad-based, caused by lower volumes and a cost base that was too high relative to activity levels. Orkla Food Ingredients has put mitigating actions in place aimed at improving efficiency and cutting costs. At Orkla Health, organic growth reached 2.7%, mainly driven by pricing. Oral Health and Wound Care delivered positive volume/mix growth, while volume and margin pressure from the omega-3 category persisted, and the raw material outlook for that category remains challenging.

Arve Regland

executive
#8

Operational cost increases, weaker omega-3 profitability, and higher food supplements advertising expenses together outweighed gains elsewhere, causing underlying EBIT to fall 5.8%. As we communicated last quarter, shutting three factories will keep dragging on results until the end of 2027. Orkla India's results came out on the 4th of August. Organic growth reached 9.7%, or 11% if you strip out the effect of a 60 million government grant recognized in the prior-year quarter. Pricing drove most of that growth, mirroring elevated raw material prices — especially chili and coriander — while volume growth came in at 1.7%. Contributions were positive from both the domestic and international business. Underlying EBIT fell 4.1%. Strip out the prior-year grant, and underlying EBIT growth was slightly positive. Moving to the European Pizza Company, consumer sales rose 8.4%, helped by same-store sales growth. Menu innovation and wider distribution fueled that consumer sales growth. Organic growth was flat, since weaker third-party sales in Kotipizza's wholesale business canceled out consumer sales growth. Underlying EBIT growth was 4.7%, powered by consumer sales growth and mix effects. Finally, at Orkla Home Care, organic revenues dropped 2.7%, yet favorable product and customer mix effects pushed underlying EBIT up 12%.

Arve Regland

executive
#9

The Health and Sports Nutrition Group posted organic revenue growth and underlying EBIT growth that were broad-based. In summary, we keep executing against our three strategic priorities. There is still more work for us to do when it comes to organic growth and volume development. Costs continue to improve at a number of portfolio companies, while at others measures have recently been launched that are aimed at lifting profitability. We have also kept strengthening the portfolio and deploying capital in line with our priorities. Our financial targets remain something we are committed to, and we look forward to setting out our long-term ambitions at the Capital Markets Day on the 1st of December. With that, following a short break, we will open for Q&A.

Annie Bersagel

executive
#10

Thanks for rejoining us. The Q&A portion starts now, and we'll kick things off with the video questions. Kindly keep in mind that you should raise your hand and switch your camera on. Our first question comes from Petter Nystrøm at ABG, as I see it.

Petter Nystrøm

analyst
#11

Thanks to you both. I hope my voice and video are coming through. You mention that Middle East effects remained modest in Q2, yet you still point to somewhat elevated costs down the road. Could you put some numbers on those headwinds as we move into the second half, and how much of them do you believe pricing can counterbalance? Thank you.

Arve Regland

executive
#12

It's kind of twofold, Petter, since clearly Jotun is the company hit hardest. As we mentioned during the presentation, the near-term effect came in below what we had expected in the first quarter outlook for Jotun. They are seeing substantial price increases, so that is going to put pressure on margins down the road. Being very precise and putting a number on it is extremely difficult, because the situation shifts daily, frankly. For the remaining companies, it's really much the same as what you observed in the first quarter, especially for energy, for transportation, packaging. We continue to see elevated input costs that will weigh, but the picture is somewhat more positive than what we saw in the Q1, at least for the short term, meaning the latter part of this year. Then as we move into 2027, once again, uncertainty remains, because everything depends on how this conflict develops. Being more precise and quantifying it is very difficult.

Petter Nystrøm

analyst
#13

Got it. If there's time for one more question. You touched briefly on how Food Ingredients is developing as you walked through the segments here. When would you expect those mitigating actions to begin, say, lifting EBIT here? Thank you.

Arve Regland

executive
#14

Most of these mitigating actions fall under SG&A. OFI is about to kick off several of them. I wouldn't count on a major effect right away — more over a somewhat longer horizon, which is to say starting next year and continuing beyond. We aren't in a position to put a number on how big this will be, but it sits very high on OFI's agenda. Naturally, the goal is to move profitability, at least over the medium and longer term.

Petter Nystrøm

analyst
#15

That's great. I'll rejoin the queue after that.

Annie Bersagel

executive
#16

Our next question appears to come from Andrei Condrea at UBS.

Andrei Condrea

analyst
#17

Good morning, and thanks for taking my questions. I have two, if I may. First, on the Easter phasing — much like in Q1, you had a benefit in your foods businesses, and now, obviously, you've got a headwind. Could you help us quantify that headwind, at least on an aggregate basis, and get down to what the underlying growth was for either the consolidated portfolio companies or your foods and snacks and OFI? My second question really concerns the 2026 outlook, mostly how you see organic sales growth progressing from here. Do you expect an acceleration in the back half of the year versus where we are today? Thank you.

Arve Regland

executive
#18

Yeah, so beginning with the Easter impacts — like we mentioned, I think we’re just restating what we said during the first quarter: during Q1, the Easter effects did have an impact. That wasn’t the main portion of the positive effects in Q1, and then in Q2 the situation is reversed. To get a view of the underlying performance, looking at the first-half figures really is preferable, since that removes the Easter impacts and provides a clearer picture of the underlying pace at each of the portfolio companies. On the outlook, we don’t provide any outlook regarding top-line development; instead, as we stated on the call, we are not pleased with overall top-line growth and volumes for the companies consolidated during the quarter and for the first half, which means our ambition is at minimum to improve performance going forward — though we can’t be any more precise than that.

Andrei Condrea

analyst
#19

Got it. Thanks a lot.

Annie Bersagel

executive
#20

I don't see any further video questions coming in, and nothing has come through on the web either. So with that, I believe that was the final question. Before we wrap up, I'd like to remind everyone that our third quarter results will be reported on the 6th of November. And then, as was already noted, our Capital Markets Day takes place on the 1st of December. We hope you'll join us for that. With that, please enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.